Yuji Yamanishi

Overview

Explore the profile of Yuji Yamanishi including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 14

Citations 1318

Followers 0

Related Specialties

Rheumatology

Dentistry

Cell Biology

Top 10 Co-Authors

Gary S Firestein

David L Boyle

Yoshiya Tanaka

Katsumi Eguchi

Tsutomu Takeuchi

Douglas R Green

Tatsuya Atsumi

Takao Koike

Shinsuke Yasuda

Zuoning Han

Published In

Mod Rheumatol

Ann Rheum Dis

Am J Pathol

Proc Natl Acad Sci U S A

J Bone Miner Metab

Affiliations

Soon will be listed here.

Recent Articles

Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication

Kameda H, Yamaoka K, Yamanishi Y, Tada M, Koike R, Nakajima A, et al.

Mod Rheumatol . 2023 Oct; 34(1):1-10. PMID: 37819199

Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for the treatment of RA in Japan in 1999 at a recommended dose...

Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population

Tanaka Y, Okuda K, Takeuchi Y, Katayama K, Haji Y, Yamanishi Y, et al.

Mod Rheumatol . 2022 Sep; 33(4):680-689. PMID: 36053757

Objectives: The aim of this article is to evaluate the efficacy and safety of subcutaneously administered methotrexate (MTX) for Japanese patients with active rheumatoid arthritis. Methods: MTX-naïve patients were randomized...

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, et al.

Ann Rheum Dis . 2017 Feb; 76(8):1348-1356. PMID: 28153828

Objectives: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. Methods:...

Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan...

Tanaka Y, Mori H, Aoki T, Atsumi T, Kawahito Y, Nakayama H, et al.

J Bone Miner Metab . 2015 Aug; 34(6):646-654. PMID: 26308708

We conducted a prospective multicenter study to assess early changes in the dynamics of bone metabolism in patients with systemic connective tissue diseases following commencement of high-dose glucocorticoid therapy and...

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al.

Ann Rheum Dis . 2015 Jul; 75(1):75-83. PMID: 26139005

Objectives: To evaluate efficacy and safety of combination therapy using certolizumab pegol (CZP) and methotrexate (MTX) as first-line treatment for MTX-naive, early rheumatoid arthritis (RA) with poor prognostic factors, compared...

Clinical features of patients with anti-neutrophil cytoplasmic autoantibodies targeting native myeloperoxidase antigen

Yamanishi Y, Ito-Ihara T, Nagao T, Uno K, Kobayashi S, Muso E, et al.

Mod Rheumatol . 2012 Oct; 23(5):963-71. PMID: 23085883

Objectives: Anti-neutrophil cytoplasmic autoantibodies (ANCA) are useful diagnostic markers in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used, the myeloperoxidase (MPO)-ANCA results are variable. In...

Localization of antimicrobial peptides human beta-defensins in minor salivary glands with Sjögren's syndrome

Kaneda Y, Yamaai T, Mizukawa N, Nagatsuka H, Yamachika E, Gunduz M, et al.

Eur J Oral Sci . 2009 Sep; 117(5):506-10. PMID: 19758245

Sjögren's syndrome is a common systemic autoimmune disease associated with inflammatory cells that infiltrate exocrine glands. The antimicrobial peptides human beta-defensin-1, human beta-defensin-2, and human beta-defensin-3 are expressed in various...

A case of polymyositis complicated with organizing pneumonia: case report and literature review

Oiwa H, Maeda A, Nishisaka T, Yamanishi Y, Yamana S, Takanashi A

Mod Rheumatol . 2006 Dec; 14(5):388-93. PMID: 17143698

A 54-year-old man was admitted to hospital with fever, dyspnea, and polyarthralgia. A chest radiograph showed consolidations in the bilateral lungs, and histological examination of transbronchial lung biopsy samples revealed...

p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis

Yamanishi Y, Boyle D, Green D, Keystone E, Connor A, Zollman S, et al.

Arthritis Res Ther . 2005 Jan; 7(1):R12-8. PMID: 15642132

Abnormalities in the p53 tumor suppressor gene have been detected in rheumatoid arthritis (RA) and could contribute to the pathogenesis of chronic disease. To determine whether synoviocytes from invasive synovium...

10.

HIF-1alpha is essential for myeloid cell-mediated inflammation

Cramer T, Yamanishi Y, Clausen B, Forster I, Pawlinski R, Mackman N, et al.

Cell . 2003 Mar; 112(5):645-57. PMID: 12628185

Granulocytes and monocytes/macrophages of the myeloid lineage are the chief cellular agents of innate immunity. Here, we have examined the inflammatory response in mice with conditional knockouts of the hypoxia...